Free Trial
NASDAQ:CELU

Celularity Q4 2024 Earnings Results & Report

Celularity logo
$0.61 -0.02 (-2.71%)
As of 02:50 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Celularity beat analyst expectations on both earnings and revenue in its Q4 2024 results, released May 8, 2025. The company reported EPS of -$0.59 versus the -$1.50 consensus estimate, while revenue of $18.13 million topped the $5.20 million estimate by $12.93 million.

Earnings Announcement Details

Quarter
Q4 2024
Report Date
Time
Before Market Opens
Conference Call Date
Conference Call
4:00 PM ET

Celularity EPS Results

Actual EPS
-$0.59
Consensus EPS
-$1.50
Beat/Miss
Beat by +$0.91
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 6 quarters

Celularity Revenue Results

Actual Revenue
$18.13 million
Expected Revenue
$5.20 million
Beat/Miss
Beat by +$12.93 million
YoY Revenue Growth
N/A

Celularity Q4 2024 Earnings FAQ

Celularity (NASDAQ:CELU) reported earnings of -$0.59 per share for Q4 2024, beating the consensus estimate of -$1.50. The report was announced on Thursday, May 8, 2025.

Celularity reported revenue of $18.13 million for Q4 2024, against a consensus estimate of $5.20 million.

Celularity Earnings Headlines

Your Social Security check is scheduled for a 22% cut
The U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt death spiral. Interest payments alone now top a trillion dollars a year. The Social Security trust fund is projected to run dry by 2032, which could trigger an automatic 22% cut to benefits. Between 2020 and 2022, the Fed expanded the money supply by 41%. A free 27 page report breaks down these numbers in plain English, including what central banks have been doing with gold.tc pixel
See More Celularity Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Celularity? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Celularity and other key companies, straight to your email.

About Celularity

Celularity (NASDAQ:CELU) is a biotechnology company that develops cell therapies and other products derived from the human placenta. Its platform uses cells collected after childbirth, which the company processes for potential use in regenerative medicine and treatment of disease.

The company’s research includes placental-derived natural killer cells and other cell types being developed for potential applications in cancer and other conditions. Its pipeline has included candidates such as CYNK-001, an investigational natural killer cell therapy.

Founded in 2016, Celularity is headquartered in Florham Park, New Jersey. Its work focuses on developing and manufacturing placenta-derived products for clinical and commercial use.

View Celularity Profile